Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Purchases $270,250.00 in Stock

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) major shareholder Braden Michael Leonard bought 235,000 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average price of $1.15 per share, with a total value of $270,250.00. Following the transaction, the insider now directly owns 11,787,134 shares of the company’s stock, valued at $13,555,204.10. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Braden Michael Leonard also recently made the following trade(s):

• On Monday, July 1st, Braden Michael Leonard purchased 107,434 shares of Aclaris Therapeutics stock. The shares were acquired at an average price of $1.14 per share, for a total transaction of $122,474.76.
• On Monday, June 17th, Braden Michael Leonard acquired 150,000 shares of Aclaris Therapeutics stock. The stock was acquired at an average price of $1.13 per share, with a total value of $169,500.00.
• On Thursday, June 13th, Braden Michael Leonard bought 528,621 shares of Aclaris Therapeutics stock. The shares were bought at an average price of $1.15 per share, for a total transaction of $607,914.15.
• On Tuesday, June 11th, Braden Michael Leonard purchased 1,000,000 shares of Aclaris Therapeutics stock. The stock was bought at an average cost of $1.08 per share, with a total value of $1,080,000.00.

Aclaris Therapeutics Price Performance

Shares of NASDAQ:ACRS opened at $1.14 on Wednesday. The firm has a fifty day moving average price of $1.16 and a two-hundred day moving average price of $1.17. The company has a market cap of $81.24 million, a price-to-earnings ratio of -1.05 and a beta of 0.27. Aclaris Therapeutics, Inc. has a one year low of $0.59 and a one year high of $11.12.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The company had revenue of $2.40 million during the quarter, compared to analyst estimates of $1.99 million. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. Equities research analysts expect that Aclaris Therapeutics, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Aclaris Therapeutics has a consensus rating of “Hold” and an average price target of $22.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vontobel Holding Ltd. raised its stake in Aclaris Therapeutics by 128.8% in the fourth quarter. Vontobel Holding Ltd. now owns 30,268 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 17,040 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at $39,000. SG Americas Securities LLC lifted its holdings in shares of Aclaris Therapeutics by 69.5% during the 1st quarter. SG Americas Securities LLC now owns 32,843 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 13,461 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Aclaris Therapeutics by 115.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 43,784 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 23,467 shares in the last quarter. Finally, Russell Investments Group Ltd. grew its position in Aclaris Therapeutics by 5,265.1% in the first quarter. Russell Investments Group Ltd. now owns 62,772 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 61,602 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.